151 related articles for article (PubMed ID: 34467996)
21. Lipoproteins in familial dysbetalipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration.
Zhao SP; Smelt AH; Leuven JA; van den Maagdenberg AM; van der Laarse A; van 't Hooft FM
Arterioscler Thromb; 1993 Feb; 13(2):316-23. PubMed ID: 8427867
[TBL] [Abstract][Full Text] [Related]
22. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.
Cohn JS; Tremblay M; Amiot M; Bouthillier D; Roy M; Genest J; Davignon J
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):149-59. PubMed ID: 8548416
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Lipoprotein Electrophoresis and Apolipoprotein E Genotyping in Investigating Dysbetalipoproteinemia.
Ahmed F; El-Kadiki A; Gibbons S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):378-379. PubMed ID: 28689531
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria.
Paquette M; Trinder M; Guay SP; Brunham LR; Baass A
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38625929
[TBL] [Abstract][Full Text] [Related]
25. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
26. Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia.
Hazzard WR; Warnick GR; Utermann G; Albers JJ
Metabolism; 1981 Jan; 30(1):79-88. PubMed ID: 7464557
[TBL] [Abstract][Full Text] [Related]
27. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
Vrablík M; Horínek A; Ceska R; Stulc T; Kvasnicka T
Physiol Res; 2003; 52(5):647-50. PubMed ID: 14535841
[TBL] [Abstract][Full Text] [Related]
28. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.
Mak AC; Pullinger CR; Tang LF; Wong JS; Deo RC; Schwarz JM; Gugliucci A; Movsesyan I; Ishida BY; Chu C; Poon A; Kim P; Stock EO; Schaefer EJ; Asztalos BF; Castellano JM; Wyss-Coray T; Duncan JL; Miller BL; Kane JP; Kwok PY; Malloy MJ
JAMA Neurol; 2014 Oct; 71(10):1228-36. PubMed ID: 25111166
[TBL] [Abstract][Full Text] [Related]
29. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
[TBL] [Abstract][Full Text] [Related]
30. The clinical and laboratory investigation of dysbetalipoproteinemia.
Boot CS; Luvai A; Neely RDG
Crit Rev Clin Lab Sci; 2020 Nov; 57(7):458-469. PubMed ID: 32255405
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
Mann WA; Gregg RE; Sprecher DL; Brewer HB
Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
[TBL] [Abstract][Full Text] [Related]
32. Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia.
Satny M; Todorovova V; Altschmiedova T; Hubacek JA; Dlouha L; Lanska V; Soska V; Kyselak O; Freiberger T; Bobak M; Vrablik M
J Clin Lipidol; 2024; 18(2):e230-e237. PubMed ID: 38044203
[TBL] [Abstract][Full Text] [Related]
33. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
[TBL] [Abstract][Full Text] [Related]
34. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
Smelt AH; de Beer F
Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
[TBL] [Abstract][Full Text] [Related]
36. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
Kobori S; Nakamura N; Uzawa H; Shichiri M
Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
[TBL] [Abstract][Full Text] [Related]
37. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
[TBL] [Abstract][Full Text] [Related]
38. Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab.
Morise AP; Hegele RA
J Clin Lipidol; 2019; 13(3):411-414. PubMed ID: 30930000
[TBL] [Abstract][Full Text] [Related]
39. Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) compared.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Van der Laarse A; Van 't Hooft FM
Clin Chem; 1994 Aug; 40(8):1559-66. PubMed ID: 8044997
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
